Vancouver, British Columbia — January 12, 2026 — Leads & Copy — TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) has announced the closing of its non-brokered private placement, issuing 3,322,153 units at $0.76 per unit, resulting in gross proceeds of CAD$2,524,836.28.
Each unit comprises one common share and one share purchase warrant. The warrant allows the holder to acquire an additional share at $1.00 until July 12, 2027.
Ron Nagar, CEO of TempraMed, stated that the equity financing validates the company’s strategy, technology, and momentum. He noted the company’s expansion into international markets, distribution partnerships, and product portfolio, reflecting growing institutional confidence in TempraMed’s vision. The company intends to use the proceeds for working capital and to build inventory.
In connection with the offering, the Company paid finders fees of $146,536.15 cash, issued 189,307 Shares and issued 1,500 Share purchase warrants of the Company. Each Finders Warrant entitles the finder to purchase one Share at a price of $1.00 per Finders Warrant Share until July 12, 2027.
All securities issued are subject to a statutory hold period expiring May 12, 2026.
The company also reported the results of its Annual General and Special Meeting of Shareholders (AGM), where the nominees listed in the Management Information Circular dated November 10, 2025 were elected as directors. Over 42% of outstanding shares were represented at the AGM. Ilan Cohen, Ron Nagar, Nancy Goertzen, John Sinclair and Julia Becker were re-elected as directors, and Ran Enoch was newly elected to the board.
Mr. Enoch has experience in online businesses, start-ups, enterprises and governmental clients. He has experience in acquisition and management of established digital assets, in addition to managing e-commerce sales of over US$1 billion, web development initiatives and investments in start-ups.
Shareholders also approved the appointment of MNP LLP as auditors and the adoption of the Company’s Equity Incentive Plan, allowing the issuance of up to 14,687,069 stock options, restricted share units, deferred share units and performed share units to eligible participants, subject to regulatory approvals. The voting results of the AGM were posted to the Company’s profile at www.sedarplus.ca on December 19, 2025.
TempraMed Technologies Ltd. develops patented, FDA-registered thermal insulation devices for temperature-sensitive medications. Its product line includes VIVI Cap and VIVI Epi.
Investors interested in learning more about TempraMed are encouraged to contact the Company at ir@tempramed.com.
Julia Becker, Vice President, Capital Markets, can be contacted at T: +1 (604) 785-0850 or E: julia@tempramed.com.
Brenda Zeitlin, Vice President, Marketing, can be contacted at brenda@tempramed.com
Source: TempraMed Technologies Ltd.
